Adams Respiratory still neutral, Merrill says

Adams Respiratory Therapeutics Inc. was maintained by Merrill Lynch analyst Gregg Gilbert at a neutral rating as sales data show the cough/cold season may have started earlier than last year's season. The company's Mucinex products are highly dependent on the timing of onset, strength and duration of the cough/cold season, Merrill said. Further data should indicate whether the recent rise in doctor's office visits for flu is just a blip or the beginning of a trend. Shares of the Chester, N.J., specialty pharmaceutical company were down $1.29, or 3.17%, at $39.37 on volume of 806,430 shares versus the three-month running average of 274,136 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.